Full Text Available

Note: Clicking the button above will open the full text document at the original institutional repository in a new window.

Evaluation of the effectiveness of dose individualisation to achieve therapeutic vancomycin concentrations

Thesis (MMed)--Stellenbosch University, 2017.

Saved in:
Bibliographic Details
Main Author: Abulfathi, Ahmed Aliyu
Other Authors: Decloedt, Eric
Format: Thesis
Language:en_ZA
Published: Stellenbosch : Stellenbosch University 2017
Subjects:
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1867614104688001024
access_status_str Open Access
author Abulfathi, Ahmed Aliyu
author2 Decloedt, Eric
author_browse Abulfathi, Ahmed Aliyu
Decloedt, Eric
author_facet Decloedt, Eric
Abulfathi, Ahmed Aliyu
author_sort Abulfathi, Ahmed Aliyu
collection Thesis
description Thesis (MMed)--Stellenbosch University, 2017.
format Thesis
id oai:scholar.sun.ac.za:10019.1/102655
institution Stellenbosch University (South Africa)
language en_ZA
last_indexed 2026-06-10T12:46:44.579Z
license_str Not specified — see source repository
provenance_str_mv Harvested via OAI-PMH from SUNScholar — Stellenbosch University Repository
publishDate 2017
publishDateRange 2017
publishDateSort 2017
publisher Stellenbosch : Stellenbosch University
publisherStr Stellenbosch : Stellenbosch University
record_format dspace
source_str SUNScholar — Stellenbosch University Repository
spelling oai:scholar.sun.ac.za:10019.1/102655 Evaluation of the effectiveness of dose individualisation to achieve therapeutic vancomycin concentrations Abulfathi, Ahmed Aliyu Decloedt, Eric Stellenbosch University. Faculty of Medicine and Health Sciences. Dept. of Biomedical Sciences. Dept. of Medicine. Division of Clinical Pharmacology. Vancomycin Drug monitoring Methicillin resistance Thesis (MMed)--Stellenbosch University, 2017. ENGLISH ABSTRACT: Background The glycopeptide antibiotic vancomycin is used for treatment of methicillin resistant Gram positive cocci. Adequate vancomycin plasma concentrations are related to bacterial cure. However, inter- and intra-patient variability make it difficult to achieve therapeutic vancomycin concentrations. The primary objective of this study was to determine the effectiveness of using computerised therapeutic drug monitoring (TDM) to assist in achieving therapeutic vancomycin concentrations at a tertiary hospital in South Africa. Method This was a 2-period study consisting of a retrospective 1-month observational period followed by a prospective 1-month period where computerised TDM was implemented as an intervention to assist with vancomycin dose individualisation. Prescribers were provided with guidelines on vancomycin dosing and TDM results during both study periods. During the prospective period, all vancomycin TDM results were followed by dose individualisation using computerised TDM. In addition, the area under the-concentration-time curve over minimum inhibitory concentration (AUC/MIC) was calculated to ensure a ratio of ≥400. Results The retrospective study included 77 patients with 292 vancomycin concentrations: 69% (53/77) adult and 31% (24/77) paediatric patients. The prospective study included 80 patients with 217 vancomycin concentrations measured: 69% (55/80) adult and 31% (25/80) paediatric patients. Less vancomycin TDM data were requested during the prospective period with a median (interquartile range) of 2 (1-3) samples per patient compared with 3 (1- 5) during the retrospective period. The odds ratio of achieving therapeutic trough concentrations was 3.63 (95% confidence interval (CI): 1.81 - 7.3) in the prospective period when TDM-adjusted vancomycin dosing and correct TDM procedures were applied. The use of computerised TDM in patients on continuous infusion resulted in 26% improvement in achieving therapeutic vancomycin concentrations in the prospective period (odds ratio 2.96; 95% CI: 1.19 - 7.36). In the prospective period, AUC0-24 was 400 mg·h/L or above in 71% of occasions. Conclusion The correct use of computerised TDM results in a higher frequency of therapeutic vancomycin concentrations in a middle income setting. Trough vancomycin concentrations alone correlate poorly with AUC0-24. Achieving therapeutic vancomycin concentration may strengthen antibiotic stewardship and save on TDM resources. AFRIKAANS OPSOMMING: Vancomycin, a glycopeptide antibiotic discovered nearly 60 years ago, is widely used as alternative to penicillin in treatment of severe infections caused by methicillin resistant Staphylococcus aureus (MRSA)[1–4]. Vancomycin is used for a variety of infections including cellulitis, pneumonia, sepsis, and endocarditis[1,2,5]. Since the 1980s there has been a steady rise in the number of MRSA infections and a subsequent increase in the use of vancomycin[1,4]. Vancomycin demonstrates concentration-independent killing and efficacy is associated with the area under the-concentration-time curve over minimum inhibitory concentration (AUC/MIC)[1,6–10]. Clinical efficacy is more likely to be achieved when vancomycin dosing achieves an AUC/MIC ≥400[1,6,7,11,12]. However, because of the difficulty in the clinical setting of repeated sampling to calculate AUC/MIC, trough vancomycin concentration monitoring with a target range of 10-20 mg/L is recommended as a surrogate marker for AUC0-24[1,6]. Supra-therapeutic trough concentrations (>20 mg/L) may result in nephrotoxicity and rarely ototoxicity[6], while sub-therapeutic trough concentrations ( 1 mg/L are high[13,14], as AUC/MIC ≥ 400 may not be attained despite achieving target trough concentrations. S 6 During a 3-month audit of vancomycin TDM at the tertiary academic institution, Tygerberg Hospital, Cape Town, South Africa, it was found that >60% of trough concentrations were outside the therapeutic range, which might be due to difficulty in dose adjusting vancomycin appropriately in response to TDM which required urgent intervention. Computerised TDM uses population pharmacokinetic (PK) modelling to account for inter- and intra-patient variability to predict dosing required to achieve therapeutic concentrations[15– 20]. Computerised TDM allows dose individualisation based on each patient’s unique vancomycin PK parameter values[15,20,21]. In addition, computerised TDM can be used to estimate AUC0-24 based on trough samples. However, to our knowledge there is no data on the application of computerised TDM in lowand middle-income settings to aid attaining therapeutic vancomycin targets. The primary objective of this study was to determine the effectiveness of using computerised TDM to assist in achieving therapeutic vancomycin trough concentrations at a tertiary academic hospital in South Africa. 2017-11-22T13:45:56Z 2017-12-11T10:37:34Z 2019-06-28T03:00:16Z 2017-12-05 Thesis http://hdl.handle.net/10019.1/102655 en_ZA v, 23 pages : illustrations application/pdf application/pdf Stellenbosch : Stellenbosch University
spellingShingle Vancomycin
Drug monitoring
Methicillin resistance
Abulfathi, Ahmed Aliyu
Evaluation of the effectiveness of dose individualisation to achieve therapeutic vancomycin concentrations
title Evaluation of the effectiveness of dose individualisation to achieve therapeutic vancomycin concentrations
title_full Evaluation of the effectiveness of dose individualisation to achieve therapeutic vancomycin concentrations
title_fullStr Evaluation of the effectiveness of dose individualisation to achieve therapeutic vancomycin concentrations
title_full_unstemmed Evaluation of the effectiveness of dose individualisation to achieve therapeutic vancomycin concentrations
title_short Evaluation of the effectiveness of dose individualisation to achieve therapeutic vancomycin concentrations
title_sort evaluation of the effectiveness of dose individualisation to achieve therapeutic vancomycin concentrations
topic Vancomycin
Drug monitoring
Methicillin resistance
url http://hdl.handle.net/10019.1/102655
work_keys_str_mv AT abulfathiahmedaliyu evaluationoftheeffectivenessofdoseindividualisationtoachievetherapeuticvancomycinconcentrations